Wall Street brokerages predict that Evolent Health Inc (NYSE:EVH) will announce sales of $233.90 million for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Evolent Health’s earnings, with estimates ranging from $229.70 million to $237.40 million. Evolent Health posted sales of $193.32 million in the same quarter last year, which indicates a positive year over year growth rate of 21%. The business is scheduled to report its next quarterly earnings results on Tuesday, February 25th.
On average, analysts expect that Evolent Health will report full-year sales of $844.46 million for the current financial year, with estimates ranging from $840.40 million to $847.20 million. For the next fiscal year, analysts expect that the company will report sales of $946.95 million, with estimates ranging from $888.50 million to $1.01 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow Evolent Health.
Evolent Health (NYSE:EVH) last issued its earnings results on Tuesday, November 5th. The technology company reported ($0.09) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.03. Evolent Health had a negative net margin of 15.02% and a negative return on equity of 6.93%. The company had revenue of $220.14 million during the quarter, compared to analysts’ expectations of $217.90 million. During the same period last year, the company posted ($0.04) earnings per share. The firm’s quarterly revenue was up 46.8% compared to the same quarter last year.
A number of research analysts have issued reports on EVH shares. Cowen set a $18.00 target price on shares of Evolent Health and gave the company a “buy” rating in a report on Wednesday, August 7th. Cantor Fitzgerald set a $16.00 target price on shares of Evolent Health and gave the company an “overweight” rating in a report on Wednesday, August 7th. ValuEngine raised shares of Evolent Health from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Piper Jaffray Companies increased their target price on shares of Evolent Health from $10.00 to $12.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. Finally, Zacks Investment Research lowered shares of Evolent Health from a “buy” rating to a “hold” rating in a research report on Tuesday, August 6th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Evolent Health presently has an average rating of “Buy” and an average price target of $15.75.
Evolent Health stock traded up $0.39 during mid-day trading on Wednesday, reaching $9.50. The company had a trading volume of 1,210,589 shares, compared to its average volume of 1,101,149. Evolent Health has a 1 year low of $5.50 and a 1 year high of $26.96. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.19 and a quick ratio of 1.19. The company has a market capitalization of $778.41 million, a P/E ratio of -27.14 and a beta of 1.07. The stock’s 50-day simple moving average is $7.78 and its 200-day simple moving average is $8.67.
Several hedge funds have recently added to or reduced their stakes in EVH. Aperio Group LLC acquired a new stake in shares of Evolent Health in the second quarter valued at approximately $40,000. ETRADE Capital Management LLC acquired a new stake in shares of Evolent Health in the second quarter valued at approximately $80,000. DekaBank Deutsche Girozentrale grew its position in shares of Evolent Health by 94.4% in the second quarter. DekaBank Deutsche Girozentrale now owns 12,061 shares of the technology company’s stock valued at $95,000 after purchasing an additional 5,856 shares during the last quarter. GABELLI & Co INVESTMENT ADVISERS INC. grew its position in shares of Evolent Health by 38.4% in the second quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 15,500 shares of the technology company’s stock valued at $123,000 after purchasing an additional 4,300 shares during the last quarter. Finally, NumerixS Investment Technologies Inc acquired a new stake in shares of Evolent Health in the second quarter valued at approximately $125,000. Institutional investors and hedge funds own 98.41% of the company’s stock.
About Evolent Health
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Featured Article: Dividend Stocks – Are They Right For You?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.